Zetagen Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Syracuse, NY. They are focused on driving breakthrough innovation in the treatment of metastatic cancers to bone and soft tissue organs, as well as osteologic interventions. Zetagen's multi-patented ZetaMet technology is a first-of-its-kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone, with the goal of helping those diagnosed with metastatic bone cancers and individuals needing osteologic intervention.
Zetagen Therapeutics has developed a series of novel therapies that address metastatic cancers at progressive stages. Their therapies are designed to suspend cancer, inhibit pain, and regenerate bone, and can be administered when the lesion is first detected through a minimally invasive outpatient procedure. With multiple Breakthrough Device Designations from the FDA, Zetagen's discoveries have the potential to create a new treatment paradigm for patients living with metastatic bone lesions and other osteologic conditions.
Generated from the website